CompletedNCT02611752
Repeated-Dose Opioid Blockade With CAM2038
About this title
Read the official source — NCT02611752Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Overland Park and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateOctober 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 47
- Sponsor
- Braeburn Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02611752
- Official title
Show the full official title
A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Overland Park · Lexington · New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Braeburn Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including CAM2038.
Who was this study for?
Listed age limits: 18 years to 55 years.
